Technology | July 27, 2011

D3 Oncology Launches Program to Accelerate SRS/SBRT Implementations

 SABRE_Website

July 27, 2011 — D3 Oncology Solutions will begin offering a comprehensive product to radiation oncologists and surgeons to rapidly and safely implement a successful stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) program.

The product is called SABRE, based on the more accurate description of SBRT as stereotactic ablative radiation therapy (SABR). The program brings together essential components of a successful implementation of radiosurgery, including clinical training for surgeons and radiation oncology teams; accurate small-field dosimetry; peer-to-peer consultations; go-live support; reimbursement guidance; follow-up reviews of quality assurance; and claims accuracy with one of the nation's most experienced clinical and technical teams.

Despite the published patient benefits of SRS and SBRT, many cancer programs across the United States have not yet implemented this service line, even though most modern linear accelerators have capabilities to deliver radiosurgery.

"Engagement of surgeons in SRS/SBRT delivery is critical to program success but availability of training and certification is often limited. Additionally, the targeted nature of SRS/SBRT can be daunting for many physicians, especially in light of recent high-profile errors that resulted in patient injuries," said Ron LaLonde, Ph.D, DABR, chief scientific officer for D3 Oncology Solutions.

D3 is collaborating with the University of Pittsburgh Cancer Institute (UPCI), UPMC Cancer Centers and Revenue Cycle Inc., to provide best practices and peer-to-peer support for cancer centers and surgeons.  

"Our success with SRS/SBRT at UPMC Cancer Centers has been centered around the close collaboration between surgeons and radiation oncologists in the patient identification and care delivery process, providing options to patients who were not otherwise candidates for other treatment strategies," added Dwight Heron, M.D., professor of radiation oncology at the University of Pittsburgh School of Medicine and vice chairman of radiation oncology at UPCI.  "SABRE brings together the necessary knowledge and precise tools essential to replicate UPMC's SRS/SBRT success for cancer programs in other markets."

Finally, as part of a broader strategic collaboration, D3 has partnered with Revenue Cycle Inc., a radiation and medical oncology consultant, to bring programs for billing and coding training, claims accuracy review, verification of payment coverage and ongoing support for an extended period.  

For more information: www.d3onc.com

Related Content

World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
News | Proton Therapy | June 16, 2020
June 17, 2020 — RaySearch Laboratories AB launched the latest release of its widely adopted treatment planning system
Vacancy rates for radiation therapists rose substantially since 2018, according to a survey performed this year by the American Society of Radiologic Technologists. Researchers noted, however, the survey data was collected before the COVID-19 pandemic began affecting the surveyed clinical settings.

Getty Images

News | Radiation Therapy | June 05, 2020
June 5, 2020 — Vacancy rates for radiation therapists rose substantially since 2018, according to a survey performed
MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape